Treatment of Heparin-Induced Thrombocytopenia: A Critical Review

Archives of Internal Medicine

Volumn 164, Issue 4, 2004, Pages 361-369

  Hirsh, Jack ^a,b   Heddle, Nancy ^b   Kelton, John G ^b  

^a HENDERSON GENERAL HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR;

AMPUTATION; BLEEDING; DRUG SAFETY; HEART MUSCLE REVASCULARIZATION; HEPARINIZATION; HUMAN; MORBIDITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

ANTICOAGULANTS; HEPARIN; HIRUDINS; HUMANS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 1242297625     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.4.361     Document Type: Review

References (30)

1. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost. 1992;68:95-96.
2. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood. 1994;83:3232-3239.
3. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
4. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
5. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993;84:322-328.
6. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984;100:535-540.
7. Laster J, Cikrit D, Walker N, Silver D. The heparin-induced thrombocytopenia syndrome: an update. Surgery. 1987;102:763-770.
8. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
9. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood. 1991;78:2194-2197.
10. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost. 1993;70:554-561.
11. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
12. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
13. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
14. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
15. Greinacher A, Janssens U, Berg G, et al, Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999;100:587-593.
16. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99:73-80.
17. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
18. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatraban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
19. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002;57:177-184.
20. Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001;86:1170-1175.
21. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85:950-957.
22. Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001;119(suppl):321S-336S.
23. Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs. 1997;54:903-924.
24. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood. 1989;73:1592-1596.
25. Keng TB, Chong BH. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-hirudin. Br J Haematol. 2001;114:394-396.
26. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23:503-516.
27. Greinacher A. Treatment of heparin-induced thrombocytopenia. Thromb Haemost. 1999;82:457-467.
28. Schiele F, Vuillemenot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 1995;50:20-25.
29. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost. 1993;70:386-388.
30. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:V275-V284.